BNTC vs SRPT
BNTC: Benitec Biopharma is a biotechnology company advancing a proprietary 'silence and replace' gene therapy platform to address rare genetic disorders like OPMD. SRPT: Sarepta Therapeutics is a leader in genetic medicine, specializing in innovative RNA-targeted and gene therapies to treat rare neuromuscular diseases like Duchenne muscular dystrophy.
Side-by-side fundamentals
| Metric | BNTC | SRPT | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $8.75 | $18.21 | |
| Market cap | $305M | $1.9B | |
| Net margin | -23528.8% | -32.5% | SRPT higher |
| Operating margin | -23044.1% | -31.8% | SRPT higher |
| ROE | -25.7% | -62.5% | BNTC higher |
| ROA | -24.9% | -21.3% | SRPT higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.55 | BNTC lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | -20.4% | |
| Revenue CAGR (3y) SEC XBRL | -93.0% | +33.1% | SRPT higher |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 0.81 | 1.56 | |
| 1-year return as of 2026-10-08 close | -37.9% | -22.1% | SRPT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.